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Abstract
This review describes the changes that have been implemented in the Tumor–Node–Metastasis (TNM)-based staging of breast
cancers by the new, 8th editions of the relevant Union for International Cancer Control (UICC) and American Joint Committee on
Cancer (AJCC) publications. After giving a background for TNM being the common language of cancer staging and related
activities like cancer treatment and registration, it summarizes not only the changes but reviews some highlights important for
pathologists, and lists and comments on the differences between the publications and diagnostic practices based on them. A
section is dedicated to the prognostic stages of breast carcinomas introduced in the AJCC Cancer Staging Manual, but not
mentioned in the UICC TNM classification of malignant tumors. A few issues that are not appropriately covered by TNM
according to the authors’ view (e.g., multifocal tumors, larger lymph node metastases identified by molecular methods, the
heterogeneous prognosis of M1-defined stage IV disease) close the review with the final thoughts raising the vision of a potential
loss of the common staging language.
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Introduction
An effective communication requires someone who com-
municates (e.g., the speaker, the author), someone who
receives the message (the receiver), a communication
channel, and very importantly a common system of sym-
bols, i.e., a common language.
It has been recognized for a long time that local (only),
regional (with spread to nearby lymph nodes), and meta-
static (with hematogenous spread to distant organs) can-
cers have a worsening prognosis, and many cancers can
be traced to follow this stepwise progression. This has
become the basis of staging carcinomas, including breast
cancers. Since its introduction, the Tumor-Node-
Metastasis (TNM) system, based on the work of Pierre
Denoix in the 1940s, has become a worldwide means to
describe the anatomic extent of cancer and determine its
stage; it is therefore the common language of tumor stag-
ing. This common language recognizes six main objec-
tives: (1) to aid clinicians in treatment planning, (2) to
give some indications on prognosis, (3) to assist in the
evaluation and comparison of treatment results, (4) to fa-
cilitate the exchange of information between different
treatment centers, (5) to contribute to the continuing in-
vestigation of malignant tumors, and (6) to support cancer
control activities [1].
The TNM name implies that features of the primary
Tumor (often the size, but also other aspects like the re-
lation to surrounding structures), features of regional
lymph Nodes (often the number and/or location of
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involved nodes, but also other aspect as the size of the
nodal involvement or the presence of extracapsular exten-
sion), and the presence or absence of distant Metastasis
reflect the prognosis of the tumor.
It has also been recognized that stage does not reflect the
biology of the tumor, which was at first characterized by its
grade. Although grade is a good reflection of tumor aggres-
siveness, at present, it is certainly insufficient alone to reflect
prognosis and predict response to specific treatments.
Therefore, components of disease stage must be
complemented with a number of other factors to better de-
scribe what can be expected from a specific cancer or a group
of similar cancers.
As most languages, the TNM system also continues to
evolve, and in sequence, the 8th edition appeared at the end
of 2016. The new edition includes a number of new parame-
ters. This review aims to cover the modifications of the 8th
edition within the context of breast cancer and breast pathol-
ogy. TNM followed by the relevant edition number will refer
to the given edition throughout the text. The review will not
reproduce the definitions of each category and stage, for this
the readers should consult the original publications [1, 2].
The TNM staging books
For those dealing with oncological diseases, the TNM-based
staging system has two main sources. One is issued by the
Union for International Cancer Control (Union Internationale
Contre le Cancer; UICC) under the name of TNM
Classification of Malignant Tumors (UICC-TNM) [1]. The
content of this book is updated on the basis of interactions
between experts in the TNM Core Committee, Evaluation
Committee, Prognostic Factors Committee, 21 National and
Regional Committees, and Expert Panels [3]. The other source
is the AJCC Cancer Staging Manual of the American Joint
Committee on Cancer (AJCC; AJCC-TNM) [2], which was
updated on the basis of the interactions of 18 expert panels, 7
AJCC Cores, authors from 22 countries representing 6 conti-
nents, and very importantly, defined and mentioned levels of
evidence [2, 4]. The first covers breast carcinomas on 8/272
pages (1.9 × 12.8 × 19.2 cm), whereas the second allocates
much more space to the issue on 40/1024 pages (5.1 ×
21.6 × 27.9 cm). These two sources should—in theory—re-
flect the same staging principles and definitions.
Unfortunately, there have been convergences and divergences
through the years. Discrepancies in wording through the 6th
and 7th editions have led, for example, to different interpreta-
tions of what constitutes isolated tumor cells (a node-negative
staging category) or micrometastasis (a node-positive status)
[5–7]. Despite the wish to have a common language, we still
see a statement at the UICC Help desk: BAlthough there
should be no differences in definitions and wording between
the AJCC and UICC TNM classifications, unfortunately some
have occurred^ [8]. The first important discrepancy is the date
of implementation of the new TNM-based staging. The UICC
Help desk states that the new TNM is active from January
2017 [8], whereas the AJCC-related resources explain why
this should be implemented at a national level from January
2018 [9]. Delaying the introduction is reasonable, as the books
appeared only in December 2016 and were out of stock until
early 2017. To overcome the problems of implementation, it is
recommended to add the edition of the TNM used [8].
Languages change over time as part of their evolution, and
generally this is a slow process, although some more or less
permissive codifications of proper usage are formulated from
time to time. The new editions of the TNM-related books can
be considered as an analogy to such linguistic codifications.
On the basis of the advice given, a proper TNM classification
should look something like this: T1miN0M0 (TNM7).
Although the advice to include the edition is meant to avoid
misunderstandings during 2017 where some users might be
using TNM7 and others TNM8, this may be useful at any
time. For example, the pN1a (TNM5) category is converted
to pN1mi from TNM6 on and is therefore not equivalent with
the pN1a (TNM6–8).
Changes, highlights, and differences
in the traditional stage defining categories
There is a list of errata which is eight pages long at the mo-
ment, but does not include corrections related to the chapter on
breast cancer [10]. Little if anything has changed in the TNM
categories of UICC-TNM. When comparing UICC-TNM7
[11] and UICC-TNM8 [1], there is only one small difference
in the wording of the pN1b and pN1c categories.
In contrast, when one compares the AJCC-TNM7 [12] or
the UICC-TNM8 [1] with the AJCC-TNM8 [2], there is one
marked difference in the categories. This is the exclusion of
lobular carcinoma in situ (LCIS), including its variants from
the pTis (AJCC-TNM8) category. The change is based on the
lack of level I evidence for its malignant character and also
insufficient proof for its variants to be different. LCIS is there-
fore called a benign entity. This, theoretically, also affects the
rare pTis(Paget) category since the category is defined with
the presence of Paget’s disease and the exclusion of coexisting
invasive or in situ carcinoma. (Only 7/114 cases had no asso-
ciated invasive or in situ carcinoma in one of the largest single
institution collection of Paget’s disease [13].)
It is true that lobular neoplasia (atypical lobular hyperplasia
and LCIS together) is generally perceived differently from
ductal carcinoma in situ (DCIS). For example, its extent is
not to be measured (Bis unreliable, unnecessary, and unhelp-
ful^), or it is categorized as B3 on core needle biopsies [14],
and it is not reported as margin involvement, when it is present
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in the inked margin. However, the pleomorphic variants of
LCIS and/or LCIS associated with comedo necrosis are often
viewed differently. These may be classified as B5 on core
needle biopsies [15] and, as such, have been suggested to be
associated with concomitant invasive cancer in up to 40% of
the cases [16]. The current European Society of Medical
Oncology clinical practice guidelines suggest that the surgical
treatment of pleomorphic LCISmay be similar to that of DCIS
and radiotherapy could also be considered [16], whereas the
current National Comprehensive Cancer Network guidelines
version 2.2017 for breast cancer also recommends excision of
pleomorphic LCIS identified on core needle biopsy [17].
Although this is not entirely new, it may be worth to high-
light that the size limits of the (p)T1–3 categories do not ex-
actly match the written definition. Tumor size measurement
can be done in a number of ways; some pathologists use the
Vernier scales for this purpose and have tenth-of-millimeter
units [18]. With the rules of rounding to the closest millimeter,
and taking into account the defense to use this rule for
microinvasive carcinomas [2], the practical definitions of tu-
mor sizes change as follows: pT1mi, 0.1–1 mm; pT1a, 1.1–
5.4 mm; pT1b, 5.5–10.4 mm; pT1c, 10.5–20.4 mm; pT2,
20.5–50.4 mm; and pT3, ≥ 50.5 mm.
Using different sources, the diagnosis of the (p)T4d cate-
gory reflecting the presence of inflammatory breast carcinoma
(IBC) may also be different. Through several editions, the
UICC-TNM books use a note BDiffuse browny induration of
the skin with an erysipeloid edge, usually with no underlying
mass^ to mark this entity [1]. In contrast, the AJCC-TNM8 is
much more restrictive in allocating a carcinoma to the (p)T4d
category. It is stressed that IBC is a clinical–pathological di-
agnosis, with a number of clinical requisites and pathological
confirmation of the underlining malignancy. The erythema/
edema (peau d’orange sign) must be diffuse, involving at least
one third of the breast, and the tumor must have a rapid evo-
lution with less than 6 months from the first symptoms to the
diagnosis of breast carcinoma [2]. This latter recommendation
aims to separate IBC from locally advanced breast cancer
producing inflammatory and skin changes in the later course
of the disease. The longer specification makes it clear that
dermal lymphatic invasion is common in IBC, but is not nec-
essary for its diagnosis, nor is its single presence without clin-
ical symptoms of IBC sufficient to make this diagnosis and
classification [2]. AJCC-TNM7 also covered the issue when
all features of IBC were present, but < 1/3 of the breast was
involved, by advising to classify these rare cases as T4b or
T4c [12]. Although AJCC-TNM8 has no specific coverage of
this issue, it seems reasonable to apply the rule of the previous
edition.
The (p)N categories have not been modified. For proper
use, it may be stressed that the use of pathologic
(microscopic) confirmatory methods of nodal involvement
before the removal of the primary tumor results in a clinical
N category. Qualifiers for either fine needle aspiration cytolo-
gy or core needle biopsy (f) and sentinel node biopsy (sn) are
to be added behind, to reflect this degree of confidence in
nodal staging and to contrast it with staging based on palpa-
tion or imaging (e.g., cN1(f) or cN1(sn) versus cN1). The pN
category mandates the definitive removal of the primary tu-
mor and lymph node(s) [2]. The definition of isolated tumor
cells has not changed; they are reflected in the N0(i+)/cN0(i+)
or the pN0(i+) category, but the UICC-TNM8 also allows for
pN0(mol+) and pN0(mol−) categories to reflect isolated tu-
mor cells either detected or tested but undetected by non-
morphological means [1].
No changes have been implemented in the M categories
either. Although the pM1 category exists (with microscopic
confirmation of distant metastasis), there are no pM0 and Mx
categories. Isolated tumor cells at distant sites (i.e., circulating
tumor cells in blood or disseminated tumor cells in the bone
marrow) are labeled as M0(i+) or cM0(i+) being a clinical
staging category. The UICC-TNM8 also includes the
M0(mol+) and M0(mol−) categories to reflect isolated tumor
cells detected by molecular methods or their lack after using
molecular testing [1]. The establishment of pathological
stages requires a pT and a pN category, but the results of the
metastatic work-up may be represented by either the clinical
M category or the pathological pM1 category.
After neoadjuvant treatment, the determination of the ypT
and ypN categories is based on the largest size of the largest
contiguous focus of residual invasive cancer without the in-
clusion of areas of fibrosis within the tumor bed and the in-
volved lymph node, respectively. This approach may under-
estimate residual tumor burden and differs from the residual
cancer burden estimation by the MDAnderson Cancer Center
calculator [19]. A micrometastasis defined as such before neo-
adjuvant treatment—e.g., a cN1mi(sn) category—could re-
flect much smaller tumor burden than a post-neoadjuvant ther-
apy Bmicrometastasis^ composed of a multitude of residual
nodal tumor foci (none of which exceeds 2 mm in greatest
dimension) separated by areas of regression-related fibrosis, in
a ypN1mi(sn) category. Some nodal metastatic lesions will be
categorized differently from TNM7, as the omission of areas
of treatment-related fibrosis was not made clear before. An
initial M1 category is not affected, even if the metastasis
disappears.
Stages
The comparison of UICC-TNM7 with UICC-TNM8 reveals
no changes in the definitions of stages, but there are major
differences between UICC-TNM8 and AJCC-TNM8; the lat-
ter includes a dual stage designation. Anatomic stages of
AJCC-TNM8 are identical with the stages of UICC-TNM8,
but AJCC-TNM8 also defines more complex prognostic
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stages. These are derived from a combination of the T, N, and
M categories, but in addition include data on histological
grade, estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor 2 (HER2) status-
es. In addition, gene-expression profiles are also incorporated
as possible Bdownstaging^ factors for tumors; as the 21-gene
assay was the only such assay to have reached level of evi-
dence I by the time of writing [2, 20], only this has been
included in the tabulated definitions of prognostic stages.
Based on literature review and for the moment unpublished
analysis of large datasets [2, 21], the developed prognostic
stages reflect prognostic grouping of tumors with expected
similar survival into one group (stage)/subgroup (substage).
Prognostic substages can deviate from anatomic stages
(UICC-TNM8 stages) by one or two substages in either
direction.
Some of the basic principles of prognostic staging that
modify the anatomic stage include PR negativity in ER-pos-
itive tumors, which generally Bupstages^ a breast cancer.
Although HER2 positivity was initially described as a factor
reflecting poor prognosis, the success of targeted anti-
HER2 treatment has resulted in HER2 positivity to be a
Bdownstaging^ factor for the prognostic stages. Triple-
negative tumors are generally Bupstaged^ in their prognos-
tic stage. Histological grade I to III tumors may be
downstaged or upsatged according to other factors.
Optionally, if known, any ER-positive and HER2-negative,
T1–T2 pN0M0 carcinoma with an OncotypeDx-derived re-
currence score of less than 11 would be Bdownstaged^ to stage
IA, independently of other parameters. There are a number of
possible combinations of the seven to eight prognostic stage
defining factors, and this has resulted in a nearly four-page-
long table for identifying the appropriate stage. This is not a
user-friendly table; therefore, electronic versions helping to
establish the prognostic stage can be useful. As one possibil-
ity, a basic approach in the form of a Microsoft Excel table is
presented as a supplementary file to this review.
The AJCC-TNM8 states that prognostic stages should be
used in areas of the world where the factors are available.
However, there are areas of the world where the factors may
be available, but the targeted treatment may not be available
for all [22], and this could be a bias in the staging system. It is
therefore not enough to have the given prognostic factor in-
corporated into the staging system, but it is also necessary to
be able to give the best evidence-based treatment on the basis
of the combination of prognostic and predictive factors. For
retrospective analysis and testing of the new staging system,
this may also be a limitation in some parts of the world.
Although the UICC-TNM8 completely ignores the prog-
nostic stages and does not mention them, it does not complete-
ly neglect prognostic factors of breast cancer and summarizes
them into the newly introduced prognostic grid, which is nei-
ther complete nor without controversies. For example, PR
status is not listed as an essential tumor-related prognostic
factor, but as an additional one, although it is a prognostic
stage defining factor in the AJCC-TNM8. The same applies
to Btumor profiling,^whatever this vague wording may mean:
the AJCC-TNM8 makes a distinction between different gene
expression profile-based assays on the basis of levels of evi-
dence, and the one with the highest level has become an op-
tional factor in defining prognostic stages. Obesity appears as
a patient-related (additional) prognostic factor, but the pa-
tient’s performance status (and/or the presence of comorbidi-
ties) is not mentioned anywhere.
Things that have not been incorporated
into the new editions
The fact that breast cancer screening has been introduced in
several countries, and that magnetic resonance imaging and/or
the use of large histological sections have revealed a much
larger proportion of cases with multiple tumors, was not taken
into account in the staging books. Although tumor size is a
continuous variable and identifying any cut-off value would
lead to better prognosis below and worse prognosis above the
cut-off point, there have been suggestions from a large screen-
ing trial that 15 mm would be a better cut-off value than
20 mm for distinguishing between tumors with good progno-
sis and those with bad prognosis [23]. To adhere to the previ-
ously introduced and stable pT1a to pT1c subcategories, data
collection regarding tumors falling into the 10.5–15.4 mm
range (e.g., pT1c1) and those between 15.5 and 20.4 mm
(e.g., pT1c2) could have been valuable even if this had not
immediately affected the broader stages.
Multifocality in breast cancer is a relatively poorly defined
term having at least three divergent interpretations. Firstly, a
surgical one reflects separate tumors within the same quadrant
of the breast, an interpretation that is often used in the context
of upper outer, lower outer, lower inner, and upper inner quad-
rants and fails to consider that an unlimited number of quad-
rants can be defined by rotating the four above mentioned
quadrants step by step. Some tumors being multifocal in this
way can be brought into the same quadrant by defining other
quadrants than those mentioned above. Secondly, a gross in-
terpretation requires each focus to be macroscopically or ra-
diologically identifiable and separate. This is the position
adopted by previous TNMs and TNM8 [2]. Thirdly, there is
an interpretation suggesting that any microscopically separate
tumor focus should allow the term multifocality to be used,
and worse prognosis is documented to be associated with
multifocality using this last definition [24, 25]. More than
one tumor focus can be coded in the T categories, by using
the largest size of the largest invasive tumor focus to define the
category, and adding a modifier in parenthesis behind; the
modifier may be Bm^ referring to multiplicity or a number
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referring to the number of foci, e.g., pT1c(m) or pT2(2).
However, here, the system fails to reflect the anatomic extent
of disease when it comes to stages. Even the prognostic stages
ignore the issue. Although there was an attempt by the AJCC-
TNM8 to group patients with similar outcome in identical
prognostic stages, with all other parameters identical, multifo-
cal tumors represent larger tumor burden and worse prognosis
than their unifocal but identically registered and staged pairs.
This is one example of how prognostic stages might not have
solved the issue of prognostic group formation. Multifocality
influences outcome [26], but is not mentioned in the UICC-
TNM8 prognostic grid either. There are also other parameters
which may have an impact on prognosis or prediction of treat-
ment, but lack sufficient evidence (e.g., diffuse distribution of
the in situ and/or invasive components and extent of disease
[27, 28]) and/or reproducibility (e.g., Ki67, tumor-infiltrating
lymphocytes [29, 30]), and/or relatively uniform availability
(e.g., urokinase plasminogen activator and plasminogen acti-
vator inhibitor type 1 (uPA, PAI-1) [31]) and are therefore not
used or mentioned in the prognostic grid [1] or the prognostic
stages [2, 32].
Molecular testing of sentinel lymph nodes as a means of
intraoperative assessment is used at a number of institutions.
Although current guidelines suggest that at least some of the
lymph node tissue should be evaluated by microscopy, it is
often the case that a larger part of the lymph node is used for
the molecular assay. Quantitative molecular tests such as one-
step nucleic acid amplification are found to be reliable [33, 34]
and may identify greater than isolated tumor cells type in-
volvement. There were propositions to label this as
pN1(mol+), but this has not been incorporated into TNM8
[33, 35].
Surprisingly, stage IV has remained untouched by the prog-
nostic factors. Whenever M1 (distant metastasis) is present,
the disease is put into the worse prognostic and anatomic
stage, and the anatomic and prognostic stage IV do not differ.
However, there are long-term survivors of stage IV breast
cancers [36], and these patients must have different disease–
host–treatment characteristics and interactions than those who
die within a few months. As a proof, we were able to demon-
strate survival differences in stage IV breast cancer according
to ER, PR, and HER2 statuses: patients with triple-negative
tumors had worse survival than those with ER-positive
HER2-negative tumors [37].
Final thoughts
Whether prognostic stages are useful or not will be clarified in
future years. This is a worthwhile attempt for the prognostic
grouping of patients beyond the anatomic extent of their dis-
ease to allow amore personalized classification of patients [4].
There are certainly other means to reach this aim than a
prognostic scoring system added to TNM, without altering
the basic structure (as for the prognostic stages in AJCC-
TNM8). For example, modifiers (ER, PR, HER2 statuses,
grade, proliferation index, gene expression-based scores…
etc.) considered in addition to the anatomic stage (as generally
used in treatment decision-making and as expected on the
basis of UICC-TNM8) or computer-basedmultivariate predic-
tive models like the temporarily non-functioning
Adjuvant!Online [38] or PredictPlus [39]. The system of prog-
nostic stages will require continuous maintenance with the
introduction of novel therapies, predictive factors or compan-
ion tests, and new evidences to keep patients with similar
outcomes in the same group (prognostic substage). This is
likely to make it subject to more and faster changes than the
anatomic stages, and fast changes in a language might alter
comprehensibility. As acknowledged by the authors of the
breast chapter in AJCC-TNM8 [1], the introduction of prog-
nostic stages splits the world into areas where prognostic
stages can be used and those where the anatomic staging will
remain the only one left for use. It also depends on cancer
registries and the oncological community whether they chose
to use the UICC-TNM8 and its stages (deemed to be interna-
tional on the basis of its name) or the more detailed and prac-
tical advice giving AJCC-TNM8 (being American in its
name) and its prognostic stages. Therefore, in the communi-
cation of results between different centers, the stages should
also be labeled as prognostic or anatomic, keeping in mind
that the prefix Bp^ is already used to reflect pathological stages
as opposed to clinical stages, and the prefix Ba^ may reflect
autopsy-based staging. It would be sibylline to say whether
the divergence of UICC-TNM8 and AJCC-TNM8 and of the
staging systems based on them is good or bad, but it is obvious
that the common language of cancer staging was compro-
mised, and additional specifications will be required to avoid
misunderstandings.
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